Through in silico approaches, we predict three key targets (HMGCR, FABP4, PPARγ), revealing that VD exerts a therapeutic influence on MetS by inhibiting bile secretion and modulating the PPAR signaling pathway. This evidence concerns the gene HMGCR and metabolic syndrome.